GlassScriptPhysician profile
Eleanor L Null
NPI 1841672128
$4,262.63
in general payments reported to CMS, 2019-2025
18 companies · $743 in 2025
The $743 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $94.48 · 2021: $304 · 2022: $312 · 2023: $1,307 · 2024: $902 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752 · Consulting Fee: $800 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.68 |
| Consulting Fee | $800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,031.43 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $770.30 | 2019-2025 | Air Optix |
| Coopervision INC. | $564.00 | 2019-2025 | Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $387.51 | 2023-2025 | Miebo, Xiidra, Infuse |
| Sun Pharmaceutical Industries INC. | $254.08 | 2024-2025 | |
| Harrow Eye, LLC | $231.78 | 2024 | Vevye |
| Mallinckrodt Hospital Products INC. | $166.74 | 2020-2023 | Acthar |
| Kala Pharmaceuticals, INC. | $133.17 | 2021 | |
| Ocular Therapeutix, INC. | $128.59 | 2024 | |
| Dompe US, INC. | $124.91 | 2025 | Oxervate |
| Shire North American Group INC | $117.60 | 2019 | |
| Glaukos Corporation | $110.29 | 2023 | |
| Apellis Pharmaceuticals, INC. | $101.39 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.11 | 2019 | |
| Oyster Point Pharma, INC. | $36.74 | 2025 | Ryzumvi, Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2022 | |
| Optos, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Null listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.